Dermatol. praxi. 2014;8(4):152-154
Herpes zoster, complications and postherpetic neuralgia, prevention
- Ambulance všeobecné a estetické dermatologie, Nemocnice Na Homolce, Praha
Herpes zoster, or shingles, is a secondary infection with the varicella-zoster virus. Primary infection is typical for childhood, causing chickenpox.
It most commonly affects children aged three to six years. During the period of primary infection, the virus travels along the sensory nerve
from the skin to the appropriate ganglion where it remains in a latent state. Herpes zoster occurs as a result of reactivation of latent viruses.
It is an inflammatory disease of the posterior horns of the spinal cord or of brain cells with skin involvement. Postherpetic neuralgia that is often
treatment-resistant is the most frequent complication. The best way to prevent this complication is early diagnosis and treatment. Since April
2014, vaccine against herpes zoster has been available in the Czech Republic as the first among central and eastern European countries.
Keywords: Varicella – zoster virus, varicella, herpes zoster, postherpetic neuralgia, pain, antiviral drugs, prevention
Published: December 1, 2014 Show citation
References
- Havlík J. Infekční nemoci - příručka pro praktické lékaře, Galen, Praha, 1998: 221.
- Gross M. Příručka léčebné lokální anestezie, Grada, Praha 1997: 214.
- Albe - Fessard D. Bolest - mechanismy a základy léčení, Grada, Praha 1998: 224.
- Ambler Z, Bednařík J, Keller O. Doporučený postup pro léčbu neuropatické bolesti, Čes. A Slov. Neurol. Neurochir., 2002; 65(98): 135-138.
- Opavský R. Postherpetická neuralgie a její léčba, Dermatologia pre praxi, Solen, 2009: 74-75.
- Hales CM, Harpaz R, Joesoef MR, Bialek SR. Examination of links between herpes zoster incidence and childhood varicella vaccination. Ann Intern Med 2013; 159: 739-745.
Go to original source... 
Go to PubMed... - Tseng H-F, Smith N, Harpaz R, Bialek Stephanie R, Sy Lina S, Jacobsen SJ. JAMA, January 12, 2011; 305(2): 160-166.
- Ortega-Sanchez IR. Decision and cost-effectiveness analyses of herpes zoster vaccination in adults 50 years of age and older. [Presentation] Atlanta, GA: US Department of Health and Human Services, CDC; 2013.
- Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82: 1341-1349. Go to original source... Go to PubMed...
- Bednařík J, Ambler Z, Opavský J, et al. Standard pro farmakoterapii neuropatické bolesti. http://www.czech-neuro.cz/att/s/o/9/phpso9CRP.pdf nebo http://www.nrc.cz/files/NPBOL_VO-0-03.
- Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs RJ. Neurologic complications of the reactivation of varicella-zoster virus [published correction appears in N Engl J Med. 2000;342(14): 1063] N Engl J Med. 2000; 342(9): 635-645. Go to original source... Go to PubMed...